MoonLake Immunotherapeutics, a clinical stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland. Show more
Location: Dorfstrasse 29, Zug, 6300, Switzerland | Website: https://www.moonlaketx.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
628M
52 Wk Range
$5.95 - $62.75
Previous Close
$9.89
Open
$9.82
Volume
4,559,646
Day Range
$9.25 - $10.13
Enterprise Value
124.4M
Cash
425.1M
Avg Qtr Burn
-41.6M
Insider Ownership
11.03%
Institutional Own.
84.38%
Qtr Updated
06/30/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Sonelokimab Details Hidradenitis suppurativa | Phase 3 Data readout | |
Sonelokimab Details Psoriatic arthritis | Phase 3 Data readout | |
Sonelokimab Details Hidradenitis suppurativa | Phase 3 Data readout | |
Sonelokimab Details Axial spondyloarthritis | Phase 2 Data readout | |
Sonelokimab Details Palmoplantar pustulosis | Phase 2 Data readout | |
Sonelokimab Details Psoriatic arthritis and Axial spondyloarthritis | Phase 2 Initiation |